Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17747
Title: The acute and residual effects of escalating, analgesic-range doses of ketamine on driving performance: A simulator study.
Authors: Hayley, Amie C;Green, Maja;Downey, Luke A;Stough, Con K K;Keane, Michael;Shiferaw, Brook;Kostakis, Panagiota;Shehabi, Yahya
Affiliation: Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Victoria, Australia
Program of Critical Care and Perioperative Medicine, School of Clinical Sciences Monash Health, Victoria, Australia
Department of Oncology, Monash Health Translation Precinct, Monash University, Clayton, Victoria, Australia
Institute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia
Forensic Science South Australia (FSSA), Adelaide, South Australia, Australia
Issue Date: 18-May-2018
EDate: 2018-05-18
Citation: Progress in neuro-psychopharmacology & biological psychiatry 2018; online first: 18 May
Abstract: Ketamine hydrochloride elicits potent psychotomimetic and neurobehavioural effects which make it incompatible with driving; however, the direct effect on driving performance is yet to be assessed. Using an open label, within-subjects protocol, 15 males and 5 females (mean age = 30.8 years) were administered three fixed, stepwise increasing sub-anaesthetic doses of intravenous (IV) ketamine solution [(i) 8 mg/h IV infusion plus 30 mg bolus, (ii) 12 mg/h IV infusion and (iii) 20 mg/h infusion]. Whole blood ketamine and norketamine concentrations were determined at each treatment step and at 2 h post-infusion. Driving performance was assessed at baseline, at each treatment step and at 2 h post-treatment using a validated computerised driving simulator. Standard Deviation of Lateral Position (SDLP) and Steering Variability (SV) were assessed. Linear Fixed Effect Modelling indicated a main effect for time (dose) for SDLP (F[4,72] = 33.22, p < 0.0001) and SV (F[4,72] = 4.65, p < 0.002). Post-hoc analyses revealed significant differences from baseline at each treatment step for SDLP (all p < 0.001), and for 12 mg/h treatment step for SV (p = 0.049). Post-treatment driving performance returned to baseline levels. Weak positive linear associations were observed between SDLP and whole blood ketamine concentrations (R2 = 0.11, β = 29.96, p = 0.001) and norketamine (R2 = 0.09, β = 28.87, p = 0.003). These findings suggest that even under highly controlled conditions, ketamine intoxication significantly alters simulated driving performance. At the highest dose, ketamine produced changes to SDLP considered incompatible with safe driving, highlighting how ketamine consumption may translate to an increased risk of road trauma.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17747
DOI: 10.1016/j.pnpbp.2018.05.015
PubMed URL: 29782960
Type: Journal Article
Subjects: Accident
Driving
Ketamine
Risk
SDLP
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.